{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:06:54Z","timestamp":1777540014021,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ahj.2007.12.009","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T10:29:52Z","timestamp":1203503392000},"page":"954-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients\u2014A Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis in Myocardial Infarction 22 (PROVE IT\u2013TIMI 22) analysis"],"prefix":"10.1016","volume":"155","author":[{"given":"Amir","family":"Lotfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.","family":"Schweiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2007.12.009_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2007.12.009_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2007.12.009_bib3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2007.12.009_bib4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Gent","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2007.12.009_bib5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2007.12.009_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2007.12.009_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2007.12.009_bib8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The antiplatelet effects of ticlopidine and clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2007.12.009_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0006-2952(90)90683-C","article-title":"The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man","volume":"40","author":"Gachet","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2007.12.009_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1616220","article-title":"ADP receptors of platelets and their inhibition","volume":"86","author":"Gachet","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2007.12.009_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"Ratz Bravo","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.ahj.2007.12.009_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennernas","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ahj.2007.12.009_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ahj.2007.12.009_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2007.12.009_bib15","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0195-668X(03)00442-1","article-title":"Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function\u2014a flow cytometry study","volume":"24","author":"Neubauer","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2007.12.009_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Saw","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2007.12.009_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.CIR.0000124581.18191.15","article-title":"Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes","volume":"109","author":"Mitsios","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2007.12.009_bib18","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ehj.2003.10.039","article-title":"Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting","volume":"25","author":"Gorchakova","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2007.12.009_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02201-4","article-title":"Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)\u2013TIMI 22 trial","volume":"89","author":"Cannon","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2007.12.009_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacc.2005.11.025","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2007.12.009_bib21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2007.12.009_bib22","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1001\/archinte.164.18.2051","article-title":"Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study","volume":"164","author":"Serebruany","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2007.12.009_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1160\/TH03-12-0738","article-title":"ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin","volume":"92","author":"Piorkowski","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2007.12.009_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/09537100400028776","article-title":"The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg\/day) for 5 weeks in patients with acute coronary syndromes","volume":"16","author":"Mitsios","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2007.12.009_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/0953710412331272532","article-title":"Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention","volume":"15","author":"Smith","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2007.12.009_bib26","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.0000099507.32936.C0","article-title":"Effects of statins on platelet inhibition by a high loading dose of clopidogrel","volume":"108","author":"Muller","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2007.12.009_bib27","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","article-title":"Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention","volume":"111","author":"Hochholzer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2007.12.009_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0735-1097(00)00817-2","article-title":"Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy","volume":"36","author":"Moshfegh","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2007.12.009_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(03)00626-X","article-title":"Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies","volume":"92","author":"Wienbergen","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2007.12.009_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","article-title":"Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial","volume":"50","author":"Saw","year":"2007","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870307010332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870307010332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:36:53Z","timestamp":1757569013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870307010332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0002870307010332"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2007.12.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients\u2014A Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis in Myocardial Infarction 22 (PROVE IT\u2013TIMI 22) analysis","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2007.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}